Company news

Argenica Therapeutics Ltd news in 2026

Argenica Therapeutics Ltd's news releases, calls and decks from 2026, newest first.

View company

Becoming a substantial holder

November 4, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 29, 2026

New Mechanism Findings Offer Insights Into Phase 2 Signal

October 19, 2026

New Mechanism Findings Offer Insights Into Phase 2 Signal

October 19, 2026

Notice of Annual General Meeting/Proxy Form

October 19, 2026

Change of Director's Interest Notice

September 28, 2026

AGM Date & Closing Date for Director Nominations

September 22, 2026

Concussion Data Selected for Neurotrauma Congress

September 14, 2026

Appendix 4E & Annual Report to 30 June 2026

August 26, 2026

Appendix 4G & Corporate Governance Statement

August 26, 2026

Notification of cessation of securities - AGN

August 13, 2026

ARG007 Shows Significant Neuroprotection in Concussion Study

July 15, 2026

ARG007 (Xaranetide) Completes All Three FDA Requested Assays

June 10, 2026

WHO Confirms Xaranetide as INN for ARG-007

June 9, 2026

IND Application Advanced With Successful Completion of Assay

May 20, 2026

Clinical Advisory Committee Established to Advance Phase 2b

May 13, 2026

Presentations at European Stroke Organisation Conference

March 25, 2026

Argenica Receives $3.97m R&D Tax Incentive Cash Rebate

March 16, 2026

Half Yearly Report and Accounts

February 10, 2026

Successful Applicaton for EMA Paediatric Waiver

February 1, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 27, 2026

Decks in 2026